Statera Biopharma Management

Management criteria checks 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Key information

Mike Handley

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.8yrs
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	2yrs

Recent management updates

Recent updates

Statera Biopharma updates on Nasdaq Listing Status

Sep 12

Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq

Aug 25

CEO Compensation Analysis

How has Mike Handley's remuneration changed compared to Statera Biopharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$92m
Jun 30 2022	n/a	n/a	-US$101m
Mar 31 2022	n/a	n/a	-US$104m
Dec 31 2021	US$3m	US$540k	-US$102m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$411k	US$252k	-US$12m

Compensación vs. Mercado: Datos insuficientes para determinar si la remuneración total de Mike es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Mike con los resultados de la empresa.

CEO

Mike Handley (51 yo)

2.8yrs

Tenure

US$2,873,818

Compensation

Mr. Michael Kevin Handley, also known as Mike, serves as President, Chief Executive Officer, Director and Chairman of the Board at Sparta Healthcare Acquisition Corp. (upon closing of the merger with old C...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Handley	CEO, President & Chairman of the Board	2.8yrs	US$2.87m	no data
Christopher Zosh	Executive VP of Finance	1.9yrs	no data	no data
Robert Buckheit	Chief Technology Officer	3.8yrs	no data	no data

2.8yrs

Average Tenure

51yo

Average Age

Equipo directivo experimentado: STABEl equipo directivo de la empresa se considera experimentado (2.4 años de antigüedad media).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Handley	CEO, President & Chairman of the Board	2.8yrs	US$2.87m	no data
Uday Saxena	Independent Director	1.8yrs	no data	no data
Blake Hawley	Independent Director	1.8yrs	no data	no data
Satish Chandran	Director	2.2yrs	no data	no data

2.0yrs

Average Tenure

61.5yo

Average Age

Junta con experiencia: STABno se consideran experimentados ( 1.7 años de permanencia media), lo que sugiere un nuevo consejo.

Statera Biopharma Management

Management criteria checks 1/4

Key information

Recent management updates

Statera Biopharma, Inc., Annual General Meeting, Dec 16, 2022

Statera Biopharma, Inc. Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Statera Biopharma, Inc. Announces Executive Changes

Statera Biopharma, Inc. Announces Resignation of Peter Aronstam as Chief Financial Officer

Recent updates

Statera Biopharma Receives Notice from Nasdaq Regarding Delisting and Suspension of Trading in the Company's Common Stock

Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index

Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index

Statera Biopharma, Inc., Annual General Meeting, Dec 16, 2022

Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million.

Statera Biopharma Plans to Regain Compliance with Nasdaq Listing Rule

Statera Biopharma, Inc. Auditor Raises 'Going Concern' Doubt

Statera Biopharma updates on Nasdaq Listing Status

Statera Biopharma, Inc. Announces Board Changes

Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq

Involuntary Petition Filed Against Statera Biopharma, Inc.

High number of new and inexperienced directors

High number of new and inexperienced directors

Statera Biopharma, Inc. Announces Executive Changes

Statera Biopharma, Inc. Announces Resignation of Peter Aronstam as Chief Financial Officer

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

Statera Biopharma, Inc., Annual General Meeting, Mar 24, 2023

Statera Biopharma, Inc. Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Statera Biopharma Announces Changes to Board of Directors

Statera Biopharma, Inc. Receives Central Institutional Review Board Approval to Conduct A Phase 3 Clinical Trial for STAT-201 in the Treatment of Pediatric Crohn’s Disease

Statera Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Statera Biopharma, Inc. Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease

Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Statera Biopharma, Inc. Announces FDA Lifts Clinical Hold on Entolimod

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age